Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
MESONEW YORK, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on use of Ryoncil® (remestemcel-L-rknd) since commercially available in March 2025 for the approved label in children 2 months and older with steroid-refractory acute graft-versus-host disease (SR-aGvHD). Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food & Drug Administration (FDA) for any indication.1
Mesoblast Announces Changes to Board of Directors' Leadership Roles
MESONEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.
Mesoblast Participation at Piper Sandler Conference
MESONEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2–4, 2025.
James M. O’Brien Appointed Chief Financial Officer at Mesoblast
MESONEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that in connection with the Company’s transition to a fully integrated commercial organization it has appointed James M. O’Brien as its US-based Chief Financial Officer (CFO). Jim has extensive experience in all aspects of financial management and planning having spent the majority of his career with multi-national public and private companies in the life sciences, biotechnology, and pharmaceutical industries.
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
MESO(NASDAQ:MESO) NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblast’s option, following shareholder approval, to repay or reduce the amount owing to its secured lenders under the existing loan agreements and for general working capital purposes.
Mesoblast Financial Results and Corporate Update Webcast
MESONEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2025.
Reported Earlier, Mesoblast Advances FDA Engagement On Revascor Accelerated Approval For Heart Failure And Ryoncil Label Expansion For Adult GvHD Patients
MESOReported Earlier, Mesoblast Secures 7-Year FDA Orphan-Drug Exclusivity For Ryoncil In Steroid-Refractory Pediatric Graft Versus Host Disease
MESOReported Earlier, Mesoblast Extends Ryoncil Coverage To Over 100M Lives In The U.S., Including Medicaid And Commercial Payers
MESOReported Earlier, Mesoblast Confirms U.S. Origin Status For Allogeneic Cell Therapies, Exempting Products From New Tariffs
MESOReported Earlier, Mesoblast Files Type B FDA Meeting Request To Advance Revascor Toward Accelerated Approval In Ischemic Heart Failure With Inflammation
MESOReported Earlier, Mesoblast's Ryoncil Begins First Pediatric Treatments In U.S. After Medicaid Coverage Expansion for SR-aGvHD
MESOReported Earlier, Mesoblast's Ryoncil Gains Comprehensive Drug Pricing Compendia Access In The U.S.
MESOMesoblast H1 2025 EPADS $(4.20) Down From $(3.72) YoY; Revenue $3.156M Down From $3.388M YoY
MESOReported Earlier, Mesoblast's Ryoncil Gains Spotlight At Tandem Meetings Following FDA Approval For Pediatric SR-aGvHD
MESOTrading Halt: Halt status updated at 6:55:00 AM ET: Quotation Resumption: News and Resumption Times
MESOTop 2 Health Care Stocks That Are Ticking Portfolio Bombs
MESOTrading Halt: Halted at 4:00:59 a.m. ET - Trading Halt: Halt News Pending
MESOJefferies Downgrades Mesoblast to Hold
MESOWhat's Going On With Mesoblast Shares Thursday?
MESOMesoblast Limited (NASDAQ:MESO) stock is trading higher Thursday after the company announced the U.S. Food and Drug Administration (FDA) approved Ryoncil.
Piper Sandler Maintains Overweight on Mesoblast, Raises Price Target to $15
MESOMesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges
MESOMesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in the U.S.
Reported Earlier, Mesoblast's RYONCIL Becomes The First FDA-Approved Mesenchymal Stromal Cell Therapy In The U.S
MESO